U.S. Stem Cell, Inc. (USRM) financial statements (2020 and earlier)

Company profile

Business Address 1560 SAWGRASS CORPORATE PKWY
SUNRISE, FL 33323
State of Incorp. FL
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 11000
Cash and cash equivalents 11000
Receivables 00000
Inventory, net of allowances, customer advances and progress billings 0000 
Inventory 0000 
Other undisclosed current assets 00 00
Total current assets: 21000
Noncurrent Assets
Property, plant and equipment 00000
Deposits noncurrent assets 0000 
Other undisclosed noncurrent assets 00000
Total noncurrent assets: 00000
TOTAL ASSETS: 22000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 22225
Accounts payable 11122
Accrued liabilities 11112
Employee-related liabilities     0
Interest and dividends payable     1
Settlement liabilities 00   
Debt 1200 
Derivative instruments and hedges, liabilities   001
Due to related parties 00000
Deferred revenue and credits000 
Other undisclosed current liabilities 32335
Total current liabilities: 666611
Noncurrent Liabilities
Long-term debt and lease obligation 1111 
Long-term debt, excluding current maturities 1111 
Capital lease obligations00   
Liabilities, other than long-term debt 0000 
Deferred revenue and credits00  
Deferred gain on sale of property 0
Due to related parties    0 
Other undisclosed noncurrent liabilities 1111 
Total noncurrent liabilities: 3222 
Total liabilities: 998811
Stockholders' equity
Stockholders' equity attributable to parent, including: (7)(7)(8)(8)(11)
Preferred stock   00 
Common stock 0000 
Treasury stock, value    (0) 
Additional paid in capital 123120116115109
Accumulated deficit (130)(128)(124)(122)(120)
Other undisclosed stockholders' equity attributable to parent     1
Total stockholders' equity: (7)(7)(8)(8)(11)
TOTAL LIABILITIES AND EQUITY: 22000

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 76322
Revenue, net6322
Cost of revenue
(Cost of Goods and Services Sold)
 (2)(2)(1)(1)(1)
Gross profit: 54211
Operating expenses (6)(4)(3)(4)(6)
Other undisclosed operating income     1
Operating loss: (1)(1)(1)(3)(4)
Nonoperating income (expense) (1)(3)(1)11
Investment income, nonoperating 0(2)000
Interest and debt expense 0(0)031
Income (loss) from continuing operations before equity method investments, income taxes: (2)(4)(2)1(1)
Loss from equity method investments     (0)
Other undisclosed income (loss) from continuing operations before income taxes (0)0(0)(3)(1)
Loss from continuing operations before income taxes: (2)(3)(2)(2)(2)
Income tax benefit     0
Net loss: (2)(3)(2)(2)(2)
Other undisclosed net loss attributable to parent     (0)
Net loss available to common stockholders, diluted: (2)(3)(2)(2)(2)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (2)(3)(2)(2)(2)
Comprehensive loss, net of tax, attributable to parent: (2)(3)(2)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: